Inovalon Holdings Inc (NASDAQ: INOV) has reported several quarters of strong bookings and appears poised to deliver positive financial surprises going ahead, after years of posting disappointing results, according to KeyBanc Capital Markets.
KeyBanc’s Donald Hooker upgraded Inovalon to Overweight while maintaining a price target of $22.
After a few years of Inovalon underperforming financial expectations, the stock seems to have been “left for dead” by investors, Hooker said in the note.
He added, however, that the company could beat expectations going ahead, as it seems to be back on a growth trajectory and Street estimates remain low.
Inovalon has generated an annualized contract value of $156 million, representing 70% year-on-year growth. This includes a series of deals with UnitedHealth Group Inc (NYSE: UNH), Molina Healthcare, Inc. (NYSE: MOH) and Humana Inc (NYSE: HUM).
The company could generate revenues of more than $700 million in 2019, of which more than 80% could consist of recurring subscription fees in growing verticals, like Medicare Advantage, Hooker said.
The analyst believes Inovalon could achieve revenue growth in 2020, along with around 50 basis points of EBITDA margin expansion, driven by economies of scale on G&A (general and administrative) expenses.
Shares of Inovalon were up 3.71% at $16.22 at the time of publishing.
Stocks That Achieved 52-Week Highs Monday Morning
Stocks that Broke Yearly Highs Friday Morning
Latest Ratings for INOV
|Aug 2019||Upgrades||Sector Weight||Overweight|
|Feb 2019||Initiates Coverage On||Buy|
View More Analyst Ratings for INOV
View the Latest Analyst Ratings
See more from Benzinga
- DA Davidson Out Bullish On Landec: 'We Can Justify A Constructive Stance'
- Hormel Foods To Continue Navigating Rough Waters In Near Term, BMO Says
- Intuit Has Substantial Growth Runway, Bullish KeyBanc Says After Q4 Beat
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.